Sorafenib in the Treatment of Virus-Related HCC: Differences Between HCV and HBV.

Hepatitis B- and C-virus (HBV and HCV) infections contribute to hepatocellular carcinoma (HCC) development through several different mechanisms. In addition to a diverse molecular background, HCC subtypes also show differences in their metabolic profiles, suggesting that prevention and treatment might require the integration of multiple different approaches. We here analyzed the response of two HCC cell lines representative of different virus-related etiology, namely Hep3B (HBV+) and HUH7 (permissive to HCV replication) to sorafenib treatment. Our findings suggest that virus-related specificities influence treatment response in HCC, along with molecular, metabolic and microenvironmental factors. These differences have to be taken into account in the design of future clinical trial aimed to improve HCC patients' outcome.
Competing Interests: Serena De Matteis, Martina Ghetti, Laura Gramantieri, Giorgia Marisi and Andrea Casadei-Gardini declare that they have no conflicts of interest.
(© 2021 De Matteis et al.)